Long-term Sequelae in Ebola Virus Disease Survivors Receiving Anti-Ebola Virus Therapies in the Democratic Republic of the Congo: A Prospective Cohort Study

Simple item page
dc.contributor.authorAngèle Dilu-Keti
dc.contributor.authorTamara Tovar-Sanchez
dc.contributor.authorBenjamin Cuer
dc.contributor.authorAntoine Nkuba-Ndaye
dc.contributor.authorDaniel Mukadi‐Bamuleka
dc.contributor.authorEric Panzi-Kalunda
dc.contributor.authorRichard Kitenge-Omasumbu
dc.contributor.authorJunior Bulabula-Penge
dc.contributor.authorFabrice Mambu-Mbika
dc.contributor.authorPlacide Mbala‐Kingebeni
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T14:29:09Z
dc.date.available2026-03-22T14:29:09Z
dc.date.issued2025
dc.descriptionCitaciones: 1
dc.description.abstractDespite improved survival with monoclonal antibody therapy, our findings highlight a high incidence of neurologic sequelae in the REGN-EB3 group and musculoskeletal sequelae in the ZMapp group as compared with the remdesivir group, as well as among older survivors, women, and those with comorbidities. These results underscore the need for targeting long-term care to effectively manage post-Ebola sequelae.
dc.identifier.doi10.1093/ofid/ofaf436
dc.identifier.urihttps://doi.org/10.1093/ofid/ofaf436
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/46789
dc.language.isoen
dc.publisherOxford University Press
dc.relation.ispartofOpen Forum Infectious Diseases
dc.sourceInstitut de Recherche pour le Développement
dc.subjectMedicine
dc.subjectEbola virus
dc.subjectHazard ratio
dc.subjectCohort
dc.subjectProspective cohort study
dc.subjectOutbreak
dc.subjectCohort study
dc.subjectPediatrics
dc.subjectDisease
dc.subjectInternal medicine
dc.titleLong-term Sequelae in Ebola Virus Disease Survivors Receiving Anti-Ebola Virus Therapies in the Democratic Republic of the Congo: A Prospective Cohort Study
dc.typearticle

Files

Collections

Artículo Científico Publicado